Search research articles
Contact Us
Filters
Showing results (191-200 of 286) with videos related to
Page
of 29
Sort By:
Scientific Reports
|
September 10, 2020
Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma
Kunal S Patel, Jingwen Yao, Catalina Raymond, et al.
Research Square
|
October 4, 2023
Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients
Richard G Everson, Willy Hugo, Lu Sun, et al.
Journal of Neuro-Oncology
|
September 15, 2020
Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas
Hiroyuki Tatekawa, Akifumi Hagiwara, Hiroyuki Uetani, et al.
Nature Communications
|
May 8, 2024
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Richard G Everson, Willy Hugo, Lu Sun, et al.
Journal of Neuro-Oncology
|
March 11, 2021
Preferential tumor localization in relation to <sup>18</sup>F-FDOPA uptake for lower-grade gliomas
Hiroyuki Tatekawa, Hiroyuki Uetani, Akifumi Hagiwara, et al.
Scientific Reports
|
February 28, 2019
Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry
Ararat Chakhoyan, Jingwen Yao, Kevin Leu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 7, 2017
Detection of immune responses after immunotherapy in glioblastoma using PET and MRI
Joseph P Antonios, Horacio Soto, Richard G Everson, et al.
Neuro-Oncology
|
November 9, 2021
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib
Benjamin M Ellingson, Grace Hyun J Kim, Matt Brown, et al.
Journal of Neuro-Oncology
|
September 2, 2022
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
Satoka Shidoh, Ricky R Savjani, Nicholas S Cho, et al.
Neuro-Oncology Advances
|
April 28, 2026
Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab
Collin T Le, Francesco Sanvito, Chuyin Yang, et al.
Page
of 29
Search research articles
Search
Showing results (191-200 of 286) with videos related to
Sort By:
Page
of 29
Scientific Reports
|
September 10, 2020
Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma
Kunal S Patel, Jingwen Yao, Catalina Raymond, et al.
Research Square
|
October 4, 2023
Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients
Richard G Everson, Willy Hugo, Lu Sun, et al.
Journal of Neuro-Oncology
|
September 15, 2020
Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas
Hiroyuki Tatekawa, Akifumi Hagiwara, Hiroyuki Uetani, et al.
Nature Communications
|
May 8, 2024
TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial
Richard G Everson, Willy Hugo, Lu Sun, et al.
Journal of Neuro-Oncology
|
March 11, 2021
Preferential tumor localization in relation to <sup>18</sup>F-FDOPA uptake for lower-grade gliomas
Hiroyuki Tatekawa, Hiroyuki Uetani, Akifumi Hagiwara, et al.
Scientific Reports
|
February 28, 2019
Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry
Ararat Chakhoyan, Jingwen Yao, Kevin Leu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 7, 2017
Detection of immune responses after immunotherapy in glioblastoma using PET and MRI
Joseph P Antonios, Horacio Soto, Richard G Everson, et al.
Neuro-Oncology
|
November 9, 2021
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib
Benjamin M Ellingson, Grace Hyun J Kim, Matt Brown, et al.
Journal of Neuro-Oncology
|
September 2, 2022
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation
Satoka Shidoh, Ricky R Savjani, Nicholas S Cho, et al.
Neuro-Oncology Advances
|
April 28, 2026
Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab
Collin T Le, Francesco Sanvito, Chuyin Yang, et al.
Page
of 29